Routine Screening for the Presence of Adulteration in Raw Materials Using Automated Nuclear Magnetic Resonance Spectroscopy

References

1. 1.↵
   1. Guerrini M.,
   2. Beccati D.,
   3. Shriver Z.,
   4. Naggi A.,
   5. Viswanathan K.,
   6. Bisio A.,
   7. Capila I.,
   8. Lansing J. C.,
   9. Guglieri S.,
   10. Fraser B.,
   11. Al-Hakim A.,
   12. Gunay N. S.,
   13. Zhang Z.,
   14. Robinson L.,
   15. Buhse L.,
   16. Nasr M.,
   17. Woodcock J.,
   18. Langer R.,
   19. Venkataraman G.,
   20. Linhardt R. J.,
   21. Casu B.,
   22. Torri G.,
   23. Sasisekharan R.

   Oversulfated chondroitin sulfate is a contaminant in heparin associated with adverse clinical events. Nat Biotech. 2008, 26 (6), 669–675.

   OpenUrlCrossRefPubMedWeb of Science
2. 2.↵
   1. Kishimoto T. K.,
   2. Viswanathan K.,
   3. Ganguly T.,
   4. Elankumaran S.,
   5. Smith S.,
   6. Pelzer K.,
   7. Lansing J. C.,
   8. Sriranganathan N.,
   9. Zhao G.,
   10. Galcheva-Gargova Z.,
   11. Al-Hakim A.,
   12. Bailey G. S.,
   13. Fraser B.,
   14. Roy S.,
   15. Rogers-Cotrone T.,
   16. Buhse L.,
   17. Whary M.,
   18. Fox J.,
   19. Nasr M.,
   20. Dal Pan G. J.,
   21. Shriver Z.,
   22. Langer R. S.,
   23. Venkataraman G.,
   24. Austen K. F.,
   25. Woodcock J.,
   26. Sasisekharan R.

   Contaminated heparin associated with adverse clinical events and activation of the contact system. N. Engl. J. Med. 2008, 358 (23), 2457–2467.

   OpenUrlCrossRefPubMedWeb of Science
3. 3.↵
   1. Abernethy D.

   Adulteration of drugs and foods: compendial approaches to lowering risk. Clin. Pharm. Ther. 2009, 85 (4), 444–447.

   OpenUrlPubMed
4. 4.↵
   1. Wen Z.-Q.,
   2. Chen G.,
   3. Luo Y.,
   4. Li G.,
   5. Masatani P.,
   6. Cao X.,
   7. Bondarenko P.,
   8. Phillips J.

   Assessment of spectroscopic techniques for adulteration detection of raw materials used in biopharmaceutical manufacturing. Am. Pharm. Rev. 2012, 15 (1), 26–35.

   OpenUrl
5. 5.↵
   1. Pauli G.,
   2. Jaki B.,
   3. Lankin C.

   Quantitative 1H NMR: development and potential of a method for natural products analysis. J. Nat. Prod. 2005, 68 (1), 133–149.

   OpenUrlCrossRefPubMed
6. 6.↵
   1. Pauli G.,
   2. Jaki B.,
   3. Lankin D.

   A routine experimental protocol for qHNMR illustrated with Taxol. J. Nat. Prod. 2007, 70 (4), 589–595.

   OpenUrlPubMedWeb of Science
7. 7.↵
   U.S. Food and Drug Administration. Guidance for Industry: Q2B Validation of Analytical Procedures: Methodology. Rockville, MD, November 1996.
8. 8.↵
   1. Malz F.,
   2. Jancke H.

   Validation of quantitative NMR. J. Pharm. Biomed. Anal. 2005, 38 (5), 813–823.

   OpenUrlCrossRefPubMed
9. 9.↵
   1. Holzgrabe U.

   Quantitative NMR spectroscopy in pharmaceutical applications. Prog. Nucl. Magn. Reson. Spectrosc. 2010, 57 (2), 229–240.

   OpenUrlCrossRefPubMed
10. 10.↵
    1. Lachenmeier D.,
    2. Humpfer E.,
    3. Fang F.,
    4. Schutz B.,
    5. Dvortsak P.,
    6. Sproll C.,
    7. Spraul M.

    NMR-spectroscopy for nontargeted screening and simultaneous quantification of health-relavant compounds in roods: the example of melamine. J. Agric. Food Chem. 2009, 57 (16), 7194–7199.

    OpenUrlPubMed
11. 11.↵
    1. Keire D.,
    2. Trehy M.,
    3. Reepmeyer J.,
    4. Kolinski R.,
    5. Ye W.,
    6. Dunn J.,
    7. Westernberger B.,
    8. Buhse L.

    Analysis of crude heparin by (1)H NMR, capillary electrophoresis, and strong-anion-exchange-HPLC for contamination by over sulfated chondroitin sulfate. J. Pharm. Biomed. Anal. 2010, 51 (4), 921–926.

    OpenUrlCrossRefPubMed